To evaluate efficacy and safety of three drug combinations in patients with community acquired pneumonia and acute exacerbation of chronic bronchitis
- Conditions
- Health Condition 1: null- community acquired pneumonia and acute exacerbation of chronic bronchitis
- Registration Number
- CTRI/2012/01/002347
- Lead Sponsor
- Dr Sharif Tadvi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 80
Subjects 18 -65 years age of either sex who are able to give voluntary written informed consent and willing to come for follow up.
Patients with clinical signs and symptoms of CAP or AECB as per investigators discretion.
Chest X-ray findings suggestive of CAP or AECB
Subjects requiring hospitalization
Subjects with known or suspected hypersensitivity to penicillins, levofloxacin, cefpodoxime or any the constituents of the formulation.
Subjects who have received antimicrobial therapy within 7 days prior to enrollment.
Patient who severe complications of RTI.
An uncontrolled, unstable clinically significant medical condition;
Clinically significant abnormal laboratory, vital sign or ECG findings at screening.
Pregnant and lactating females.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decrease in severity of clinical signs and symptoms from baseline to the end of treatment. <br/ ><br>Radiological response to treatment. <br/ ><br>Microbiological response to the treatment. <br/ ><br>Timepoint: 14 days
- Secondary Outcome Measures
Name Time Method ILTimepoint: NI